222 related articles for article (PubMed ID: 25023990)
1. Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis.
Wang L; Li W; Lin M; Garcia M; Mulholland D; Lilly M; Martins-Green M
Carcinogenesis; 2014 Oct; 35(10):2321-30. PubMed ID: 25023990
[TBL] [Abstract][Full Text] [Related]
2. Pomegranate juice and specific components inhibit cell and molecular processes critical for metastasis of breast cancer.
Rocha A; Wang L; Penichet M; Martins-Green M
Breast Cancer Res Treat; 2012 Dec; 136(3):647-58. PubMed ID: 23065001
[TBL] [Abstract][Full Text] [Related]
3. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
[TBL] [Abstract][Full Text] [Related]
4. Pristimerin Inhibits Prostate Cancer Bone Metastasis by Targeting PC-3 Stem Cell Characteristics and VEGF-Induced Vasculogenesis of BM-EPCs.
Huang S; He P; Peng X; Li J; Xu D; Tang Y
Cell Physiol Biochem; 2015; 37(1):253-68. PubMed ID: 26302893
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
6. Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice.
Zhao M; Tang SN; Marsh JL; Shankar S; Srivastava RK
Cancer Lett; 2013 Sep; 337(2):210-7. PubMed ID: 23684930
[TBL] [Abstract][Full Text] [Related]
7. Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis.
Wang L; Ho J; Glackin C; Martins-Green M
Transl Oncol; 2012 Oct; 5(5):344-55. PubMed ID: 23066443
[TBL] [Abstract][Full Text] [Related]
8. Plumbagin, a medicinal plant (Plumbago zeylanica)-derived 1,4-naphthoquinone, inhibits growth and metastasis of human prostate cancer PC-3M-luciferase cells in an orthotopic xenograft mouse model.
Hafeez BB; Zhong W; Fischer JW; Mustafa A; Shi X; Meske L; Hong H; Cai W; Havighurst T; Kim K; Verma AK
Mol Oncol; 2013 Jun; 7(3):428-39. PubMed ID: 23273564
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator‑activated receptor γ agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis.
Qin L; Gong C; Chen AM; Guo FJ; Xu F; Ren Y; Liao H
Mol Med Rep; 2014 Aug; 10(2):695-700. PubMed ID: 24842333
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Quercetin in the Yishen Tongluo Jiedu Recipe on the Development of Prostate Cancer through the Akt1-related CXCL12/ CXCR4 Pathway.
Ning Y; Wu Y; Zhou Q; Teng Y
Comb Chem High Throughput Screen; 2024; 27(6):863-876. PubMed ID: 37259219
[TBL] [Abstract][Full Text] [Related]
11. Melittin inhibits tumor angiogenesis modulated by endothelial progenitor cells associated with the SDF-1α/CXCR4 signaling pathway in a UMR-106 osteosarcoma xenograft mouse model.
Qin G; Chen Y; Li H; Xu S; Li Y; Sun J; Rao W; Chen C; Du M; He K; Ye Y
Mol Med Rep; 2016 Jul; 14(1):57-68. PubMed ID: 27177128
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer.
Heidegger I; Fotakis G; Offermann A; Goveia J; Daum S; Salcher S; Noureen A; Timmer-Bosscha H; Schäfer G; Walenkamp A; Perner S; Beatovic A; Moisse M; Plattner C; Krogsdam A; Haybaeck J; Sopper S; Thaler S; Keller MA; Klocker H; Trajanoski Z; Wolf D; Pircher A
Mol Cancer; 2022 Jun; 21(1):132. PubMed ID: 35717322
[TBL] [Abstract][Full Text] [Related]
13. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.
Chinni SR; Sivalogan S; Dong Z; Filho JC; Deng X; Bonfil RD; Cher ML
Prostate; 2006 Jan; 66(1):32-48. PubMed ID: 16114056
[TBL] [Abstract][Full Text] [Related]
14. Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies.
Baci D; Bruno A; Cascini C; Gallazzi M; Mortara L; Sessa F; Pelosi G; Albini A; Noonan DM
J Exp Clin Cancer Res; 2019 Nov; 38(1):464. PubMed ID: 31718684
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.
Conley-LaComb MK; Semaan L; Singareddy R; Li Y; Heath EI; Kim S; Cher ML; Chinni SR
Mol Cancer; 2016 Nov; 15(1):68. PubMed ID: 27809841
[TBL] [Abstract][Full Text] [Related]
16. Pomegranate and its components as alternative treatment for prostate cancer.
Wang L; Martins-Green M
Int J Mol Sci; 2014 Aug; 15(9):14949-66. PubMed ID: 25158234
[TBL] [Abstract][Full Text] [Related]
17. Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin.
Zhou Q; Yan B; Hu X; Li XB; Zhang J; Fang J
Mol Cancer Ther; 2009 Jun; 8(6):1684-91. PubMed ID: 19509250
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model.
Shanmugam MK; Manu KA; Ong TH; Ramachandran L; Surana R; Bist P; Lim LH; Kumar AP; Hui KM; Sethi G
Int J Cancer; 2011 Oct; 129(7):1552-63. PubMed ID: 21480220
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
[TBL] [Abstract][Full Text] [Related]
20. MDM2 as a target for ellagic acid‑mediated suppression of prostate cancer cells in vitro.
Mohammed Saleem YI; Selim MI
Oncol Rep; 2020 Sep; 44(3):1255-1265. PubMed ID: 32705219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
